Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
6.74
+0.06 (0.90%)
At close: May 12, 2025, 4:00 PM
7.18
+0.44 (6.53%)
After-hours: May 12, 2025, 6:43 PM EDT
Bioventus Revenue
Bioventus had revenue of $123.88M in the quarter ending March 29, 2025, a decrease of -4.31%. This brings the company's revenue in the last twelve months to $567.70M, up 8.60% year-over-year. In the year 2024, Bioventus had annual revenue of $573.28M with 11.89% growth.
Revenue (ttm)
$567.70M
Revenue Growth
+8.60%
P/S Ratio
0.77
Revenue / Employee
$610,429
Employees
930
Market Cap
447.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 573.28M | 60.94M | 11.89% |
Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BVS News
- 6 days ago - Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Bioventus Reports First Quarter Financial Results - GlobeNewsWire
- 14 days ago - Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025 - GlobeNewsWire
- 2 months ago - Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Benzinga
- 2 months ago - Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 - GlobeNewsWire
- 4 months ago - Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - GlobeNewsWire